Home » Stocks » CCCC

C4 Therapeutics, Inc. (CCCC)

Stock Price: $34.28 USD 1.07 (3.22%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.48B
Revenue (ttm) 33.20M
Net Income (ttm) -66.34M
Shares Out 43.19M
EPS (ttm) -5.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $34.28
Previous Close $33.21
Change ($) 1.07
Change (%) 3.22%
Day's Open 32.48
Day's Range 32.48 - 35.31
Day's Volume 250,245
52-Week Range 22.40 - 48.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models –

3 weeks ago - GlobeNewsWire

– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigatio...

1 month ago - GlobeNewsWire

WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy d...

1 month ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

2 months ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

2 months ago - GlobeNewsWire

– Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 – – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 –

3 months ago - GlobeNewsWire

WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

4 months ago - GlobeNewsWire

An FDA nod on Isoray's prostate treatment using brachytherapy seeds sent ISR stock skyrocketing. There's risk with uncertain reward in this biopharma stock.

4 months ago - InvestorPlace

– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expec...

4 months ago - GlobeNewsWire

C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders.

4 months ago - Seeking Alpha

WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disea...

4 months ago - GlobeNewsWire

About CCCC

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for syn... [Read more...]

Industry
Biological Product (except Diagnostic) Manufacturing
IPO Date
Oct 2, 2020
Stock Exchange
NASDAQ
Ticker Symbol
CCCC
Full Company Profile

Financial Performance

In 2020, CCCC's revenue was $33.20 million, an increase of 55.25% compared to the previous year's $21.38 million. Losses were -$66.34 million, 94.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price forecast is 56.50, which is an increase of 64.82% from the latest price.

Price Target
$56.50
(64.82% upside)
Analyst Consensus: Strong Buy